WHO Issues Concern Over Severe Shortage of Weight-Loss Injections

Less than one in 10 individuals eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, caution the WHO as it releases its inaugural advice on the therapies.

With in excess of 1,000,000,000 people worldwide currently obese, it is urging increased and just access to GLP-1 medication.

Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.

"Our new guidelines acknowledges that obesity is a chronic disease that can be addressed with comprehensive and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are major barriers to broad availability to the jabs that can help people shift significant body mass, says the body.

Skinny Jab Shortage

Despite the current most optimistic scenario, the production of GLP-1 therapies might only reach approximately 100 million people – under 10% of the global need, per the WHO.

The guideline encourages countries and companies to widen availability, through measures such as patent sharing.

Exclusive production rights on the active ingredient – the main component of a leading brand – is set to lapse in multiple nations in 2026.

The Way Obesity Injections Function

The injections replicate a biological compound to slow digestion, reduce hunger and increase satiety so individuals consume fewer calories.

Individuals typically begin shedding pounds after several weeks of commencing the once-weekly jabs.

Studies suggests users may see weight return after a year of stopping the treatment, when their typical hunger return.

Being overweight or obese increases your likelihood for experiencing health problems, including diabetes, heart disease, stroke, and some cancers.

Excess weight impacts individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, per the WHO.